Tower Research Capital (TRC)’s Repros Therapeutics Inc. RPRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-343	Closed	–	–	4689
2016 Q4	$0	Sell	343 -1,163	-77%	-$2.02K	﹤0.01%	5116
2016 Q3	$3K	Buy	+1,506	New	+$2.98K	﹤0.01%	3008
2016 Q1	–	Sell	-3,315	Closed	-$4K	–	5857
2015 Q4	$4K	Buy	+3,315	New	+$10.6K	﹤0.01%	3375
2015 Q3	–	Sell	-268	Closed	-$2K	–	5742
2015 Q2	$2K	Sell	268 -1,293	-83%	-$10.1K	﹤0.01%	3936
2015 Q1	$13K	Buy	1,561 +1,192	+323%	+$10.7K	﹤0.01%	2618
2014 Q4	$4K	Buy	+369	New	+$3.15K	﹤0.01%	3047
2014 Q2	–	Sell	-308	Closed	-$5K	–	5492
2014 Q1	$5K	Buy	+308	New	+$5.96K	﹤0.01%	3390
2013 Q4	–	Sell	-3,677	Closed	-$99K	–	5588
2013 Q3	$99K	Buy	3,677 +2,528	+220%	+$54.2K	0.01%	1309
2013 Q2	$21K	Buy	+1,149	New	+$20.3K	﹤0.01%	1691

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Tower Research Capital (TRC)'s RPRX Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Repros Therapeutics Inc. (RPRX) in Q1 2017, closing a stake of 343 shares.

Tower Research Capital (TRC) first reported a position in RPRX in Q2 2013 and held it in 9 quarters. The position peaked at $99K in Q3 2013. 33 funds tracked by Wall St. Rank hold RPRX as of Q1 2017.

Tower Research Capital (TRC) reported no remaining Repros Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
Tower Research Capital (TRC) sold 343 Repros Therapeutics Inc. shares in Q1 2017.
Tower Research Capital (TRC) first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 9 quarters.
Tower Research Capital (TRC)'s Repros Therapeutics Inc. position peaked at $99K in Q3 2013.
33 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.